These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37749129)

  • 1. A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.
    Ozberk V; Zaman M; Lepletier A; Eskandari S; Kaden J; Mills JL; Calcutt A; Dooley J; Huo Y; Langshaw EL; Ulett GC; Batzloff MR; Good MF; Pandey M
    Nat Commun; 2023 Sep; 14(1):5963. PubMed ID: 37749129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
    Zaman M; Ozberk V; Langshaw EL; McPhun V; Powell JL; Phillips ZN; Ho MF; Calcutt A; Batzloff MR; Toth I; Hill GR; Pandey M; Good MF
    Sci Rep; 2016 Dec; 6():39274. PubMed ID: 27976706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
    Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
    PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
    Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI.
    Guzmán CA; Talay SR; Molinari G; Medina E; Chhatwal GS
    J Infect Dis; 1999 Apr; 179(4):901-6. PubMed ID: 10068585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.
    Pandey M; Wykes MN; Hartas J; Good MF; Batzloff MR
    J Immunol; 2013 Mar; 190(6):2692-701. PubMed ID: 23401589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A
    Dai CC; Yang J; Hussein WM; Zhao L; Wang X; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
    ACS Infect Dis; 2020 Sep; 6(9):2502-2512. PubMed ID: 32786276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial super-infection.
    Zaman M; Huber VC; Heiden DL; DeHaan KN; Chandra S; Erickson D; Ozberk V; Pandey M; Bailly B; Martin G; Langshaw EL; Zaid A; von Itzstein M; Good MF
    Clin Transl Immunology; 2021; 10(9):e1337. PubMed ID: 34527244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
    Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
    Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
    Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
    Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.